Proteomic identification of haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone rats

被引:10
作者
Kiga, Chizuru [1 ,4 ]
Sakurai, Hiroaki [1 ,3 ]
Goto, Hirozo [2 ,3 ]
Hayashi, Kazuko [1 ]
Shimada, Yutaka [2 ,3 ]
Saiki, Ikuo [1 ,3 ]
机构
[1] Toyama Univ, Inst Nat Med, Div Pathogen Biochem, Toyama 9300194, Japan
[2] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Japanese Oriental Med, Toyama 9300194, Japan
[3] Toyama Univ, 21 Century COE Program, Toyama 9300194, Japan
[4] Toyama New Ind Org, Toyama 9300866, Japan
关键词
ProteinChip; Biomarker; SELDI-TOF-MS; Stroke; Haptoglobin;
D O I
10.1016/j.lfs.2008.08.013
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aims: We investigated changes in the expression of plasma proteins in spontaneously hypertensive strokeprone rats (SHRSP) to identify stroke biomarkers. Main Methods and Key findings: The present analysis using surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) demonstrated that three peaks at mass/charge ratios (m/z) of 9330, 9480 and 9700 decreased in intensity during the development and progression of hypertensive stroke in SHRSPs, but not in age-matched control SHR and Wistar rats. Administration of verapamil, an L-type calcium channel blocker which was effective for hypertension in SHRSP rats, prevented the decrease in plasma protein expression. A candidate biomarker protein (m/z 9330) was identified using LC-MS/MS as haptoglobin (Hp). Immunoblotting with anti-Hp antibody demonstrated the decreased expression of both Hp alpha and Hp beta chains in SHRSP. In contrast, haptoglobin mRNA expression in the liver of SHRSPs slightly increased as compared with control rats. Significance: These findings suggest that Hp is a biomarker candidate for discriminating pathogenic alterations of stroke. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:625 / 631
页数:7
相关论文
共 29 条
[1]  
Adam BL, 2002, CANCER RES, V62, P3609
[2]   Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease [J].
Asleh, R ;
Marsh, S ;
Shilkrut, M ;
Binah, O ;
Guetta, J ;
Lejbkowicz, F ;
Enav, B ;
Shehadeh, N ;
Kanter, Y ;
Lache, O ;
Cohen, O ;
Levy, NS ;
Levy, AP .
CIRCULATION RESEARCH, 2003, 92 (11) :1193-1200
[3]  
Cazares LH, 2002, CLIN CANCER RES, V8, P2541
[4]   EFFECT OF THE HAPTOGLOBIN PHENOTYPE ON THE SIZE OF A MYOCARDIAL INFARCT [J].
CHAPELLE, JP ;
ALBERT, A ;
SMEETS, JP ;
HEUSGHEM, C ;
KULBERTUS, HE .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (08) :457-463
[5]   HAPTOGLOBIN POLYMORPHISM AND COMPLICATIONS IN ESTABLISHED ESSENTIAL ARTERIAL-HYPERTENSION [J].
DELANGHE, JR ;
DUPREZ, DA ;
DEBUYZERE, ML ;
BERGEZ, BM ;
CALLENS, BY ;
LEROUXROELS, GG ;
CLEMENT, DL .
JOURNAL OF HYPERTENSION, 1993, 11 (08) :861-867
[6]   ROLE OF HYPERTENSION IN ATHEROSCLEROSIS AND CARDIOVASCULAR-DISEASE [J].
HOLLANDER, W .
AMERICAN JOURNAL OF CARDIOLOGY, 1976, 38 (06) :786-800
[7]   The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification [J].
Issaq, HJ ;
Veenstra, TD ;
Conrads, TP ;
Felschow, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 292 (03) :587-592
[8]   Expression patterns of plasma proteins in spontaneously diabetic rats after oral administration of a Kampo medicine, Hachimi-jio-gan, using SELDI ProteinChip platform [J].
Kiga, C ;
Nakagawa, T ;
Koizumi, K ;
Sakurai, H ;
Shibagaki, Y ;
Ogawa, K ;
Goto, H ;
Saiki, I .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (06) :1031-1037
[9]   Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis [J].
Kozak, KR ;
Amneus, MW ;
Pusey, SM ;
Su, F ;
Luong, MN ;
Luong, SA ;
Reddy, ST ;
Farias-Eisner, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (21) :12343-12348
[10]  
Langlois MR, 1996, CLIN CHEM, V42, P1589